The consensus that seems to emerge from studies on colon adenocarcinoma, hepatocellular carcinoma, melanoma and lymphoma, is that the presence of granzyme B+ CD8 TIL is a favorable prognosis factor [44,58,70,77]. This evidence concerns the gene CD8A and melanoma.